menu
    • menu
    [{"orgOrder":0,"company":"CastleVax","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"NDV-HXP-S","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CastleVax","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"CastleVax \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"CastleVax \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"CastleVax","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"CVAX-01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CastleVax","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CastleVax \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"CastleVax \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals by CastleVax

    Menu

    CastleVax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CastleVax

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed

                            CastleVax

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVAX-01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : BARDA

                            Deal Size : $34.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CastleVax Receives $34M from BARDA to Advance Intranasal NDV-based COVID-19 Vaccine

                            Details : The funding aims to support the clinical development of CVAX-01 to advance in the mid-stage clinical trial studies for treatment of patients related to Covid-19 infections.

                            Brand Name : CVAX-01

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : CVAX-01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : BARDA

                            Deal Size : $34.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CastleVax

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed

                            CastleVax

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NDV-HXP-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : U.S. Department of Health and Human Services

                            Deal Size : $8.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vacc...

                            Details : The net proceeds from the funding will be used by CastleVax for the advancement of Phase 2 study of a next generation, vector-based intranasal vaccine candidate.

                            Brand Name : NDV-HXP-S

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 13, 2023

                            Lead Product(s) : NDV-HXP-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : U.S. Department of Health and Human Services

                            Deal Size : $8.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth